Clinical Trials Browser

Phase 2 × Esophageal Neoplasms × Sorafenib × Clear all

NCT00917462 2019-03-27

Sorafenib for Patients With Metastatic or Recurrent Esophageal and Gastroesophageal Junction Cancer

Phase 2 Completed

35 enrolled 11 charts

Gastrointestinal

Esophageal Neoplasms

NCT01158287 2014-12-31

Sorafenib. ICORG 06-41, V4

Phase 2 Completed

Gastrointestinal

Adenocarcinoma Of Esophagus, Esophageal Neoplasms, Stomach Neoplasms